GLP-1s for Fatty Liver (MASH/MASLD): A New Era of Treatment

For decades, the standard response to metabolic-associated fatty liver disease was frustratingly simple: lose weight, exercise, and avoid alcohol. Physicians had no medications to offer for the underlying liver pathology. That era is now definitively over. In 2024 and 2025, a convergence of regulatory approvals and landmark clinical trials has transformed fatty liver disease management — and GLP-1 receptor agonists are at the center of that transformation. Millions of Americans with MASLD or MASH who believe there is “nothing to treat” the liver directly now have meaningful, evidence-based options.

Understanding MASLD and MASH: The Terminology Has Changed

The naming of fatty liver disease was updated by international hepatology societies in 2023, and the new terminology reflects a better understanding of the disease’s metabolic nature:

• MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease) — formerly NAFLD (non-alcoholic fatty liver disease). Refers to fat accumulation in the liver (steatosis) in the context of metabolic dysfunction. Affects an estimated 30–40% of U.S. adults.
• MASH (Metabolic dysfunction-Associated Steatohepatitis) — formerly NASH. The inflammatory and fibrotic progression of MASLD. Affects approximately 5% of U.S. adults. MASH drives fibrosis progression to cirrhosis, liver failure, and hepatocellular carcinoma.

The name change from “non-alcoholic” to “metabolic dysfunction-associated” is deliberate: it centers the disease’s actual cause — insulin resistance, visceral obesity, dyslipidemia, and type 2 diabetes — rather than simply defining it by what it isn’t. This framing makes GLP-1 therapy’s role in management conceptually clear: treat the metabolic root, and the liver disease may follow.

If you are living with fatty liver disease alongside obesity or metabolic syndrome in Savannah or coastal Georgia, learn how Scale Solutions’ medical weight loss program addresses the full metabolic picture.

Myth #1: There Is No Medication for Fatty Liver Disease

This myth — common even among patients and some non-specialist physicians — is no longer accurate as of 2024–2025.

Resmetirom (Rezdiffra) became the first FDA-approved medication specifically for MASH with fibrosis when it received approval in March 2024. Resmetirom is a thyroid hormone receptor beta (THR-β) agonist that reduces hepatic lipid synthesis and promotes fatty acid oxidation in liver cells. In the MAESTRO-NASH trial, resmetirom achieved MASH resolution in 26–30% of patients (vs. ~10% placebo) and fibrosis improvement by at least one stage in 24–26% of patients (vs. ~14% placebo) at 52 weeks. This is a narrow but genuine pharmacological victory for hepatology.

Alongside resmetirom, GLP-1 receptor agonists — particularly semaglutide — have accumulated substantial evidence in MASH that is now culminating in potential label expansion.

The ESSENCE Trial: Semaglutide and MASH Histology

The ESSENCE trial — a large, randomized, placebo-controlled study published in the New England Journal of Medicine in 2025 — is the most significant GLP-1/MASH trial to date. It enrolled adults with confirmed MASH (biopsy-proven) and stage F2–F3 fibrosis, a population at meaningful risk for cirrhosis progression.

Key findings:

• MASH resolution without worsening fibrosis: Achieved in approximately 63% of semaglutide-treated patients vs. 34% of placebo — a 29-percentage-point treatment difference
• Fibrosis improvement by ≥1 stage: Achieved in approximately 37% of semaglutide patients vs. 22% of placebo
• Both MASH resolution and fibrosis improvement: Achieved in approximately 25% of semaglutide patients vs. 13% of placebo
• Liver enzymes (ALT, AST), liver stiffness measures, and other biomarkers improved significantly in the semaglutide arm

These histological improvements — confirmed on liver biopsy — demonstrate that semaglutide’s benefit in MASH extends well beyond weight loss. Histological MASH resolution in 63% of treated patients is a clinically transformative result, and it has supported Novo Nordisk’s regulatory submission for a Wegovy (semaglutide 2.4 mg) MASH indication. This approval, if granted, would make semaglutide the first GLP-1 agent with an explicit MASH label.

Myth #2: Fatty Liver Is Just a ‘Fat’ Problem — Lifestyle Is Enough

This oversimplification misrepresents the biology of MASH and leads to missed treatment opportunities.

MASH is a histopathological diagnosis involving hepatocyte ballooning (a sign of hepatocyte injury), lobular inflammation, and progressive fibrosis — none of which are directly visible or measurable without liver biopsy or validated non-invasive tests. Fat accumulation (steatosis) is just the entry point. Once fibrosis develops, the risk profile shifts substantially: F3 fibrosis is associated with markedly elevated liver-related mortality and cirrhosis progression, and lifestyle changes alone rarely reverse established fibrosis.

The Lancet hepatology literature and AASLD (American Association for the Study of Liver Diseases) practice guidance emphasize that patients with MASH and significant fibrosis (F2–F3) are candidates for pharmacological intervention, not just dietary counseling. GLP-1 agonists that produce both weight loss and direct hepatic anti-inflammatory and anti-fibrotic effects are now a legitimate first-line consideration in this population.

AASLD’s 2023–2024 practice guidance documents increasingly recognize GLP-1 agonists as part of the MASH management algorithm, particularly for patients with concurrent obesity and type 2 diabetes — the same metabolic profile that drives most MASH in clinical practice.

Myth #3: Only Weight Loss Matters — GLP-1s Don’t Benefit the Liver Directly

This myth is directly refuted by the ESSENCE data and mechanistic research.

GLP-1 receptors are expressed in hepatic stellate cells, Kupffer cells (liver macrophages), and hepatocytes. Preclinical and early clinical studies have shown that semaglutide reduces hepatic lipogenesis (fat synthesis), NF-κB-driven inflammatory signaling, and stellate cell activation (the primary driver of fibrosis) through receptor-mediated pathways that are at least partially independent of weight loss.

In the ESSENCE trial, histological improvements occurred even in patients who lost modest amounts of weight, suggesting mechanisms beyond caloric restriction. This hepatocyte-level biology explains why semaglutide produces MASH resolution rates (63%) that exceed what would be predicted from weight loss magnitude alone.

The Lancet Gastroenterology and Hepatology has published multiple mechanistic reviews confirming GLP-1 receptors as direct hepatic targets, supporting the scientific validity of using these agents for liver-specific endpoints.

Stay updated on the latest in GLP-1 research and regional clinical developments at our coastal Georgia GLP-1 news hub.

How GLP-1 Agents Compare to Resmetirom for MASH

These two drug classes address overlapping but distinct aspects of MASH:

• Resmetirom (Rezdiffra): Works directly on thyroid hormone signaling in liver cells, reducing hepatic fat content and lipotoxic injury. FDA-approved for MASH F2–F3. Does not produce significant systemic weight loss. Primary strength: direct hepatic target.
• Semaglutide (Wegovy/Ozempic): Acts on GLP-1 receptors systemically and in the liver. Produces 10–15% weight loss, reduces hepatic fat, inflammation, and fibrosis. MASH indication under regulatory review. Primary strength: full metabolic package for patients with obesity + MASH.

For patients with MASH who also have obesity and/or type 2 diabetes — which describes the majority of MASH patients clinically — a GLP-1 agonist addresses the liver disease, the metabolic driver, and the cardiovascular risk simultaneously. Resmetirom and GLP-1 agents may ultimately be used in combination for high-risk MASH patients, though combination trials are still ongoing.

Who Should Be Screened for MASH?

AASLD and major hepatology guidelines recommend MASH screening and risk stratification for patients with:

• Obesity (BMI ≥30)
• Type 2 diabetes
• Metabolic syndrome (hypertension, dyslipidemia, insulin resistance)
• Elevated liver enzymes (ALT/AST) without another explanation
• Family history of cirrhosis or liver cancer

Non-invasive tools including the FIB-4 index, liver stiffness measurement (vibration-controlled transient elastography, VCTE), and liver MRI-PDFF can stratify fibrosis risk without biopsy. Patients with FIB-4 above 1.3 warrant further evaluation. When advanced fibrosis is identified, pharmacological intervention is appropriate to consider.

If you have been told you have “fatty liver” and have never had a thorough metabolic evaluation, speak with Dr. Donald L. Gates, who works with patients in Savannah, Pooler, and Hinesville to address the full spectrum of obesity-related comorbidities.

A New Era for Liver Disease Management

The convergence of resmetirom approval in March 2024, the ESSENCE semaglutide MASH trial in 2025, and AASLD’s evolving guidance marks a true inflection point. Fatty liver disease — specifically MASH with fibrosis — is now a treatable condition with pharmacological tools that go beyond lifestyle modification. GLP-1 agonists occupy a central position in this new landscape, with direct hepatic effects, profound metabolic benefits, and an emerging label expansion that will formalize their role in MASH management.

Addressing Fatty Liver and Metabolic Health in Coastal Georgia

When it comes to GLP-1 medications, who prescribes and where the medication comes from matters enormously. Get GLP-1 treatment from a physician you trust, working with licensed, state-board-accredited compounding pharmacies and FDA-approved brand-name medications. Dr. Donald L. Gates has practiced bariatric medicine since 1999 and personally oversees every patient at Scale Solutions — only sourcing from licensed, accredited pharmacies. Serving patients in Savannah, Pooler, and Hinesville, GA. Call (912) 352-7546 or book a consultation today.

Medical Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Fatty liver disease management requires evaluation by a qualified gastroenterologist or hepatologist alongside your bariatric physician. Treatment decisions, including whether pharmacotherapy for MASH is appropriate for you, should be made with your healthcare team. Do not start or stop any medication without physician supervision.

Frequently Asked Questions

Is there now a medication specifically approved for fatty liver disease?

Yes. Resmetirom (Rezdiffra) was FDA-approved in March 2024 for metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis stages F2–F3 — the first drug ever approved specifically for this condition. Additionally, semaglutide (Wegovy) is under regulatory review for a MASH indication based on the 2025 ESSENCE trial results, which showed 63% MASH resolution in treated patients.

What did the ESSENCE trial show about semaglutide and the liver?

The ESSENCE trial, published in the New England Journal of Medicine in 2025, found that semaglutide 2.4 mg weekly achieved MASH resolution without worsening fibrosis in approximately 63% of patients with biopsy-confirmed MASH and F2–F3 fibrosis, compared to 34% with placebo. Fibrosis improvement of at least one stage occurred in 37% of semaglutide patients versus 22% with placebo.

Does GLP-1 therapy work on the liver directly, or just through weight loss?

Both. GLP-1 receptors are present in liver cells, stellate cells, and liver macrophages, and semaglutide has demonstrated anti-inflammatory and anti-fibrotic hepatic effects that occur partially independent of weight loss. In the ESSENCE trial, some patients achieved histological MASH resolution with modest weight loss, indicating direct hepatic mechanisms beyond caloric restriction.

What is the difference between MASLD and MASH?

MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease) refers to fat accumulation in the liver linked to metabolic dysfunction — the earlier, milder stage. MASH (Metabolic dysfunction-Associated Steatohepatitis) is the inflammatory, injurious progression of MASLD, characterized by hepatocyte ballooning, lobular inflammation, and fibrosis. MASH carries meaningful risks of cirrhosis and liver cancer if untreated.

How do I know if I have advanced fatty liver disease?

Non-invasive screening tools include the FIB-4 index (calculated from age, liver enzymes, and platelets), liver stiffness measurement via elastography, and MRI-based fat quantification. A FIB-4 above 1.3 warrants further evaluation. Patients with obesity, type 2 diabetes, or metabolic syndrome who have elevated liver enzymes should ask their physician about formal MASH risk stratification.